Trial Profile

An Open-label, Multicenter Phase II Study Evaluating Balstilimab Alone or Balstilimab in Combination With Zalifrelimab in Patients With Advanced Cervical Cancer

Status: Withdrawn prior to enrolment

Phase of Trial: Phase II

Latest Information Update: 01 Apr 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Balstilimab (Primary) ; Zalifrelimab (Primary)
Indications Adenosquamous carcinoma; Cervical cancer; Squamous cell cancer
Focus Adverse reactions; Therapeutic Use
Sponsors Agenus

Most Recent Events

27 Mar 2024 Status changed from recruiting to withdrawn prior to enrolment.
27 Mar 2024 Planned initiation date changed from 1 Sep 2021 to 1 Oct 2021.
25 Aug 2022 Planned number of patients changed from 160 to 177.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com